Minnesota is the problem-solving capital of America–and our businesses, from large to small, are finding solutions that will redefine the future of the global economy. They’re building what matters. | Minnesota businesses have a legacy of building things that last while changing the global economy for the better. The state boasts an extraordinary concentration of Fortune 500 companies, a fast-growing startup ecosystem that pulls in venture capital from investors worldwide, and renowned research institutions that foster innovation.
Minnesota Pavilion
Minnesota businesses have a legacy of building things that last while changing the global economy for the better. The state boasts an extraordinary concentration of Fortune 500 companies, a fast-growing startup ecosystem that pulls in venture capital from investors worldwide, and renowned research institutions that foster innovation.
LABORATORIOS CASASCO
Laboratorios Casasco is a pharmaceutical manufacturing company headquartered in Buenos Aires, Argentina. It was founded in 1876, making it one of the country’s oldest pharmaceutical companies. Our mission is to advance global health and well-being by developing pharmaceutical products of the highest quality, grounded in scientific excellence and ethical integrity. Our portfolio includes cardiovascular health, Urology, Neurology and psychiatry, Immunology, Endocrinology (e.g., diabetes), Anti-infectives, Gastrointestinal treatments, Women’s health, and preventive medicine. Born in the 19th century, walked along the 20th century, and entered the 21st century as an enduring Argentine endeavor through the centuries.
J R Biomedical
J R Biomedical is a UK based, ISO13485 certified medical diagnostics company, who have developed a panel of proprietary antibodies, and a rapid point-of-care test to detect plasma soluble Toll-like receptor 2 (sTLR2), a biomarker known to be elevated in sepsis, and infective and non-infective inflammation. UK Patent Application GB2502531.3. The imiwn sTLR2 RAPID test gives results in 10 minutes and is UKCA certified and registered with MHRA. An independent study of sTLR2 versus CRP in critically ill patients showed that sTLR2 had better specificity and sensitivity for sepsis than C-reactive protein, the most commonly used marker in the ICU. Further, low sTLR2 levels had good ability to rule out sepsis within the first 12 h of ICU stay, when clinical parameters and traditional markers of infection are often equivocal. Global licensing and distribution opportunities for the sTLR2 antibody panel and rapid test are available.
IQVIA BRASIL
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and accelerate innovations. With approximately 88,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Learn more at www.iqvia.com.
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.
HEAL ITALIA FOUNDATION
The Heal Italia Foundation it is established thanks to the European Union-funded project “Health Extended Alliance for Innovative Therapies, Advanced Lab-research and Integrated Approaches of Precision Medicine”. It represents today the Italian strategic cluster in the Life Sciences sector, with a specific focus on Precision Medicine. Headquartered in Palermo, Rome, and soon also in Milan and Brussels, it coordinates a multidisciplinary network of over 70 entities (see https://www.healitalia.eu/partner/) including 33 Universities, IRCCS, and companies. The goal is to share knowledge, research, and innovative technologies to support the Italian research and healthcare system in defining new models and approaches for the prevention, diagnosis, and treatment of chronic diseases, with primary focus on oncological, cardiovascular, metabolic, rare, and neurodegenerative conditions. The Foundation: • coordinates a network of over 600 researchers operating throughout Italy; • benefits, through its partner network, from a large project portfolio with over 250 ongoing studies, and from products and/or technologies protected by over 1000 patents; • develops new models and approaches for Precision Medicine through the use and testing of 5.0 technologies (Artificial Intelligence, Big Data, Supercomputing Systems) in preclinical, clinical, and translational fields; • supports pharmaceutical research also through the first Core Facility that brings together accredited Biobanks, GMP, Data Networks, and Cell Factories; • launched in 2023 the first National PhD Program in Precision Medicine. Acting as a Fund Agency, supports the acquisition of specific funds and grants for researchers and/or startups working on innovative projects in precision medicine. It also directly finances research projects and startups to promote applied research and technology transfer, accelerating the development and commercialization of advanced technological solutions.
Gerresheimer
Gerresheimer is an innovative system and solution provider and global partner for the pharma, biotech and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical packaging, drug delivery systems, medical devices and digital solutions. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With around 13,600 employees and over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). https://www.gerresheimer.com/en/home
Gel Coat Biomaterials, Inc.
Gel Coat Biomaterials Inc. is a top leading company in enzyme stabilization, founded on the Amoeba Hydrogel Technology (AHT) discovered and developed by Professor Madoka Takai at the University of Tokyo. AHT enhances the stability of bio-products such as enzymes and biopharmaceuticals for wide applications. First, AHT stabilizes and immobilizes enzymes used in API (Active Pharmaceutical Ingredient) manufacturing, dramatically improving the efficiency of the API production process. Second, AHT suppresses the degradation of biopharmaceuticals and enzyme-based drugs within the body for improving pharmacokinetics (PK). Third, novel enzymes for special applications are stabilized and/or immobilized. Forth, biocompatible bioelectric power generation devices for innovative implantable medical devices is developed based on AHT.
Gador S.A.
Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Viatris, MSD, Novartis, Cipla, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Sifi, Recordati, Boehringer, Viatris, MSD, Novartis, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading pharmaceutical Company that investigate, develop, manufacture and commercialize medicinal products for human use. It is based in Argentina since 1940 and today covers the whole Latin America through own affiliates or a net of exclusive distributors. Gador continuously invests in product technology, quality control and new facilities development, according to international standards and approvals such as FDA, EMA, KFDA, COFEPRIS, TGA, among others.. Our company is currently focused on innovative therapies and products, such as biopharmaceutics, oligonucleotides and gene therapies as a source of generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a long-standing experience in the commercialization of special and primary care products, either own products or licenses from world renowned companies, such as Gilead Sciences, Astellas, MSD, Boehringer Ingelheim, Recordati, Viatris, Sifi, Galderma, Besins, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease In addition, Gador´s main shareholders have created a new development company: Qualix Dot (Design on Therapies). Qualix DoT is the research and development pharmaceutical company of Qualix Ventures.The purpose of Qualix DoT is to explore, drive, and collaborate in world-class innovative projects that come from academic or industrial initiatives by mainly repurposing known compounds for new indications. Qualix DoT adopts a collaborative business model whereby it works in partnership with academic, industrial and patients’ organizations. Biopharmaceuticals – rare disease – oncology – biosimilars – CAR T – Oligonucleotides y Repurposing